In its first move towards fulfilling the president's campaign promise to reduce the cost of prescription drugs, the Trump administration released a 28-page document summarizing a number of ways to push down prices.

Most of the suggested policies are traditional right-of-center ideas that emphasize the benefits of competition and the harms of government regulation. Few of the proposed solutions are specific.

The administration points a finger at the FDA, saying that the time it takes the agency to review and approve new drugs leaves consumers with fewer generic options and higher prices. One potential solution, it suggests, is to change "the criteria for expedited review to include new molecular entities that are second or third in a class, or second or third for a given indication for which there are no generics."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.